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INVESTIGATIONS OF GENOTOXIC
ACTIVITY OF ANTIMICROBIAL/
ANTIVIRAL AGENT FS1 IN HUMAN
LYMPHOCYTES AND TUMOR CELL
A very promising antiviral and antimicrobial agent FS1
was studied for its ability to induce DNA damage and
micronuclei in human tumor cell lines HeLa and Caco2 at
concentrations of 200, 500 and 1000 μg/ml without exogenous
metabolic activation. The compound was additionally tested
for DNA damaging ability in human lymphocytes at concen
trations of 200, 400 and 800 μg/ml. Neither DNA damage
nor micronucleus formation was observed after treatment of
all types of cells with FS1. Based on these results, FS1 can
be further studied for its safety to humans for potential appli
cation in clinical medicine as an antimicrobial/antiviral drug.
Introduction. Recently very effective drug
against a number of strains of microbes and virus
es was invented and patented in Kazakhstan (KZ
Patent № 15116). FS1 is a complex of iodine with
synthesized polysaccharides, i.e., it is an iodophore,
a combination of iodine and a solubilizing agent
that releases free iodine when diluted with water.
Iodophores possess quick microbial action against
a wide variety of antimicroorganisms, e.g., bacte
ria, viruses, fungi and protozoa [1].
FS1 is very potent in veterinary medicine against
many infectious factors of microbial and viral ori
gin. Molecular mass of the compound is 32 500.
Because of its low toxicity in rodents (i.e.,
25 ml/kg is well tolerated dose, containing 19.9 g/l
of active ingredients – unpublished data of Scientific
Center for AntiInfectious Drugs, Almaty,
Kazakhstan) it is possible to use FS1 in the clini
cal medicine as microbicide, if it meets all interna
tional safety criteria. These include, in the first turn,
the studies on mutagenicity of the compound.
The compound has been tested for its muta
genicity in the Salmonella/microsome (Ames)
assay in five strains of microbes (TA 98, TA 100,
TA 102, TA 1535, TA 1538) with and without
metabolic activation at doses up to 500 μl/plate
(which was the limit of bacterial toxicity).
Completely negative results were obtained (Prof.
S. Knasm ller, Medical University of Vienna, per
sonal communication).
DNAdamaging and micronucleus (MN) induc
ing activity of FS1 in mammalian cells in in vitro
systems is unknown. The aim of this work was to
evaluate DNAdamaging activity of FS1 in human
tumor cell lines and lymphocytes, and also MN
inducing ability in human tumor cell lines.
Material and methods. Chemicals. FS1 was pro
duced in RSOE «AntiInfectious Drugs», Almaty,
Kazakhstan. All other chemicals used in experi
ments were produced by SigmaAldrich (St. Louis,
USA). FS1 is an aqueous solution of iodine–lithi
um inclusion complex with low molecular weight
αdextrin and polyvinyl alcohol. FS1 contains
also potassium iodide, lithium and sodium chlo
rides. The compound has almost the same compo
sition as iodinelithiumalphadextrin used in
some countries as a potent antimicrobial/antiviral
agent [2].
Cells. HeLa (human cervix carcinoma) and
Caco2 (epithelial colorectal adenocarcinoma)
cells were obtained from Laboratory U 322
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Marseilles, France, and cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supple
mented with 10 % (v/v) heatinactivated foetal
bovine serum and 100 U/ml penicillin/strepto
mycin. Cells were kept at 37 °С in humidified
5 % CO2 and 95 % air and were allowed to grow
in complete medium (containing serum) for 24 h
before the start of experiments. The experiments
were conducted in flasks containing 5 ml of
medium with 2 · 106 HeLa or Caco2 cells at
concentrations of FS1 100, 200, 500, 1000 and
2000 μg/ml (incubation time – 24 h). Viability of
cells was assessed by means of trypan blue dye
exclusion technique, i.e., the number of viable
cells was calculated as described earlier [3]. Cells
were identified as viable (bright yellow), com
promised (bluish), and dead (completely blue).
Only bright yellow cells were considered. Since
2000 μg/ml was highly toxic for both HeLa and
Caco2 cells (90 % dead cells), and 1000 μg/ml
of FS1 induced death only in ca. 30 % cell, the
compound was tested at doses of 200, 500 and
1000 μg/ml.
Blood samples were obtained by venous punc
ture from two male and two female healthy
donorsvolunteers (nonsmokers, 21–25 years
old). Lymphocytes were separated by centrifuga
tion (20 min, 2000 r.p.m., at room temperature)
in equal amounts of Lymphoprep («Nycomed»,
Norway), washed in phosphatebuffered saline.
One million lymphocytes were incubated for
24 h with various concentrations of FS1 (1000,
800, 400 and 200 μg/ml). The first concentration
was very toxic for lymphocytes. Eight hundred
μg/ml of the compound decreased the viability of
cells to ca. 70 %, and this concentration was
chosen as an upper limit of the compound con
centration in the study. Other tested concentra
tions of FS1 used were 400 and 200 μg/ml. In
the first experiment with lymphocytes freshly
isolated cells were used. In the second experi
ment, conducted later, lymphocytes stored at
–80 °С were used.
Comet assay. Comet (single cell gel electrophore
sis) assay was carried out as described in our recent
papers [4]. Cells were stained with ethidium bro
mide. Cells were analyzed visually by means of
LM6 microscope (USSR). One hundred cells on
each slide (3 slides per each culture, 900 cells per
experimental point or, in other words, per concen
tration) were scored as belonging to one of five
classes of comets according to tail intensity and
given a value of 0, 1, 2, 3 and 4 (from undamaged
0 to maximally damaged 4). Thus, the total score
for 100 comets (called arbitrary unit) ranges from
0 (all undamaged cells to 400 (all maximally dam
aged) [4]. Some examples of comets are presented
in Fig. 1–4.
A mean value of arbitrary units obtained from
each culture was considered as an independent vari
able. Methyl methanesulfonate (MMS) was used as
a positive control in all experiments (30.0 μg/ml,
3 h incubation) because of its high genotoxic
potency. As negative control phosphate buffered
saline (PBS) was used. Two independent experi
ments were carried out.
Micronucleus (MN) assay. The assay was con
ducted as described earlier [3]. After the growing in
the complete medium (containing serum) for 18 h,
HeLa and Caco2 cells were incubated 24 h with
FS1 at concentrations of 1000, 500 and 100 μg/ml.
Cisplatin (1.5 μg/ml) was used as a positive con
trol. As a negative control PBS was used. Three
simultaneous cultures were prepared, and the exper
iments were carried out two times. Consequently,
microscopic slides with cells were prepared for
analysis. 
Two thousand cells were studied from each slide
for cytogenetic alterations under microscope,
6000 per concentration (MBI6).
Statistical analysis. MannWhitney Utest was
applied to calculate differences between the groups.
The mean value of DNA damage which was
obtained from each culture and expressed in arbi
trary units, was considered as an independent vari
able. Three numbers obtained per concentration
in the first experiment were compared with ana
logues data from the second experiment. In no
case a significant difference was obtained. So, 6
variables of each experimental point were com
pared with 6 variables obtained from positive and
negative controls, respectively.
In the MN assay the independent variables
were number of cells with MN and total number of
MN, expressed in pro mille. Similarly, no signifi
cant differences were found between the data
obtained from both experiments. The data were
evaluated statistically as previous set of results.
The differences between three experimental
groups and negative controls were evaluated in all
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cases by means of KruskalWallis test. Also, in
experiments with human lymphocytes Kruskal
Wallis test was applied to calculate interindividual
and gender differences.
Results and discussion. Iodophores such as
povidone–iodine are broadspectrum microbi
cides with activity against bacteria, viruses, fungi
and protozoa. They consist of elementary or ion
ized iodine bound to polymer carriers (such as
poly1vinyl2pyrrolidine and dextrins), which
increase solubility and provide a reservoir of
iodine [1]. Due to the oxidizing effects of free
iodine on key groups of proteins, nucleotides,
fatty acids and the subsequent nonspecific mech
anism of cell killing, iodophores are used as
potent microbicides [1, 2].
Taking this into account, it is of interest to
study FS1 in the shortterm genotoxicity assays.
Since the compound is supposed to be used in
clinical medicine, it is mandatory and necessary to
evaluate its possible genotoxic activity [5].
We studied the activity of FS1 in two widely
used shortterm genotoxicity assays, i.e., in the
comet and MN assays, which are recommended
for testing of various compounds [6–9]. Human
lymphocytes as well as HeLa and Caco2 human
cancer cell lines are the most frequently used cell
for various kinds of investigations, including DNA
damage and MN studies [6–9].
In human HeLa and Caco2 tumor cells, FS1
at a dose of 1000 μg/ml induced about 30 % cell
death. This concentration was used as an upper
limit in our experiments since in the guidelines
for MN assays in vitro [6] concentrations which
induce about 30–50 % cell toxicity are recom
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Fig. 1. Various grades of comets in human lymphocytes. On
the left can be seen a nondamaged cell (0 comet score)
located between 2 severely damaged cells (comet score 4)
Fig. 2. Various grades of comets in human lymphocytes.
Undamagent cell is located below a cell with comet gra
te 2 (above)
Fig. 3. Lymphocyte with comet score of 4 (severely damaged)
Fig. 4. HeLa cells with comets of various grades
mended as an upper limit. Also in the comet
assay 1000 μg/ml was used as a highest concen
tration because cytotoxic action of the chemical
studied in the comet assay should not exceed
30 % [9].
The results of the experiments on potential
DNAdamaging effect of FS1 in two tumor cell
lines are presented in Table 1. It can be seen that
no genotoxic effect was found after incubation of
cells with FS1 for 24 h in both cell lines. The pos
itive control induced substantial DNA damage in
all experiments. The background DNA damage
level in both cell lines was in the range of previous
published results [3, 4]. The differences between
the three experimental groups and the negative
controls were estimated by means of Kruskal
Wallis test. No statistically significant difference
was obtained.
Human lymphocytes were more sensitive to
acute toxic action of FS1 than cancer cells since
the concentration of 1000 μg/ml was highly toxic.
Neither sex nor interindividual differences were
obtained since no statistically significant differ
ence was found when KruskalWallis test was
applied. Because of this the data were pooled.
The results of the comet assay with human lym
phocytes are presented in Table 2. As can be seen,
no significant changes compared with the nega
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Table  1
DNAdamaging activity of FS1 in human tumor 
cell lines HeLa and Caco2 (visual score, mean 
of two independent experiments)
Note. MMS – methylmethane sulfonate; PBS – phosphate
buffered saline; the difference between negative control and
FS1 treated groups was not statistically significant (Kruskal
Wallis test). *p < 0.002, **p < 0.05, MannWhitney Utest.
Compound and
concentration, 
μg/ml
Percent 
of viable cells
DNA damage 
(arbitrary units, 
mean ± SE)
HeLa
FS1 (1000)
FS1 (500)
FS1 (200)
MMS (30)
PBS
69.3 ± 1.4 *
91.2 ± 0.9
93.8 ± 1.1
86.3 ± 1.9 **
96.5 ± 1.1
16.4 ± 1.1
14.0 ± 1.0
11.5 ± 0.9
45.7 ± 2.0 *
10.0 ± 0.9
Compound and
concentration, 
μg/ml
Percent 
of viable cells
DNA damage 
(arbitrary units, 
mean ± SE)
FS1 (200)
FS1 (400)
FS1 (800)
MMS (30)
PBS
93.6 ± 0.6
93.5 ± 0.6
75.7 ± 0.9 *
86.3 ± 1.0
93.5± 0.5
10.0 ± 0.5
10.0 ± 0.5
9.4 ± 0.5
47.4 ± 0.9 *
4.9 ± 0.3
Caco2
FS1 (1000)
FS1 (500)
FS1 (200)
MMS (30)
PBS
71.8 ± 1.78 *
91.2 ± 1.14
94.8 ± 1.1
82.8 ± 2.2 **
95.5 ± 1.1
14.7 ± 1.5
12.7 ± 1.0
11.8 ± 1.4
40.4 ± 2.3 *
9.7 ± 1.2
Note. The difference between negative control and FS1
treated groups was not statistically significant (p  0.05,
KruskalWallis test). *p < 0.002, MannWhitney Utest.
Table 2
DNAdamaging activity of FS1 in human lymphocytes
(pooled data obtained from 2 male and 2 female donors,
visual score, mean of two independent experiments)
Table 3
Micronucleus inducing activity of FS1
in human cancer cell lines HeLa and Caco2 
(mean of two independent experiments)
Compound and
concentration, 
μg/ml
Percent 
of viable cells
Cells with
MN, ‰
Total number
of MN, ‰
Note. The difference between negative control and FS1
treated groups was not statistically significant (p  0.05,
KruskalWallis test). *p < 0.002, **p < 0.05, Mann
Whitney Utest.
HeLa
FS1
1000
500
200
Cisplatin
1.5
Negative con
trol (PBS)
72.0 ± 1.7 *
90.3 ± 1.3
94.5 ± 0.9
81.8 ± 1.6 **
94.5 ± 1.0
4.2 ± 0.6
3.0 ± 0.7
3.6 ± 0.4
36.6 ± 1.7 *
3.2 ± 0.3
4.4 ± 0.7
3.3 ± 0.8
4.0 ± 0.4
42.4 ± 1.9 *
3.6 ± 0.3
Caco2
FS1
1000
500
200
Cisplatin
1.5
Negative con
trol (PBS)
74.3 ± 1.6 *
90.3 ± 1.3
93.2 ± 2.0
82.5 ± 1.8 **
97.0 ± 1.0
3.2 ± 0.5
3.2 ± 0.4
2.6 ± 0.4
29.2 ±1.6*
2.6 ±0.2
3.5 ± 0.5
3.2 ± 0.4
2.6 ± 0.4
34.0 ± 1.7*
2.8 ± 0.3
tive control were observed. In addition, the dif
ferences between the three experimental groups
and the negative controls were estimated by
means of KruskalWallis test. No statistically sig
nificant difference was obtained.
Hence, FS1 showed no DNAdamaging activ
ity in the comet assay in human lymphocytes and
tumor cell lines HeLa and Caco2.
The results of the MN assay are presented in
Table 3. It can be noted that FS1 did not induce
an increase either in the number of cells with MN
or total number of MN in both cell lines.
Background levels of MN in untreated cells and
cisplatininduced MN frequencies were similar to
our previous reported results [3].
HeLa cells lack the ability to metabolize
mutagens/carcinogens because of absence of
phase I enzymes whereas Caco2 possesses
ability for metabolic activation of xenobiotics
by means of cytochromes CYP1A1, CYP1A2
and CYP1B1 [10, 11]. Human lymphocytes
possess cytochrome P450 2E1 but it is not
enough for metabolic activation of all xenobi
otics [12]. The absence of genotoxic activity of
FS1 in lymphocytes and Caco2 cells which
possess more or less drug metabolism phase I
enzymes, and also in HeLa cells suggest that
either the compound has no ability to be trans
formed into biologically active metabolites or
after the transformation of the compound
metabolites have equal genotoxic potential with
the parent compound. Our data support com
pletely negative results in the Salmonel
la/microsome assay in five strains of microbes
both with and without metabolic activation with
S9 mix (Prof. Knasmüller, personal communi
cation).
Since the tested compound is iodophore, it
would be of interest to stress that widely used rep
resentative of this kind of preparations, povidone
iodine, was found nongenotoxic in some in vitro
mutagenicity tests in bacteria and mammalian
cells as well in mouse bone marrow MN assay
[13–15].
Hence, the results obtained in the present set of
experiments are very important for the next level of
genotoxicity studies of FS1 which can be used in
clinical medicine (especially as topical microbici
dal/antiviral agent) after routine testing of safety
for humans.
А. Нерсесян, А. Ильин, M. Кулманов
ИССЛЕДОВАНИЯ 
ГЕНОТОКСИЧЕСКОЙ АКТИВНОСТИ
АНТИБАКТЕРИАЛЬНОГО/ПРОТИВОВИРУСНОГО
ПРЕПАРАТА ФС1 В ЛИМФОЦИТАХ И КЛЕТКАХ
ОПУХОЛИ ЧЕЛОВЕКА
Исследовали способность перспективного антиви
русного и антибактериального соединения ФС1 вы
зывать повреждения ДНК и микроядра в клеточных
линиях опухоли человека HeLa и Caco2 при концен
трациях 200, 500 и 1000 мкг/мл без экзогенной мета
болической активации. Соединение было дополнитель
но проверено на ДНКповреждающую способность в
лимфоцитах человека при концентрациях 200, 400
и 800 мкг/мл. Ни повреждения ДНК, ни формирова
ния микроядер не наблюдалось после обработки всех
типов клеток ФС1. На основании этих результатов,
ФС1 может быть далее изучен на предмет безопаснос
ти для возможного применения в клинической меди
цине как антибактериального/противовирусного пре
парата.
А. Нерсесян, А. Ільїн, М. Кулманов
ДОСЛІДЖЕННЯ 
ГЕНОТОКСИЧНОЇ АКТИВНОСТІ
АНТИБАКТЕРІАЛЬНОГО/ПРОТИВІРУСНОГО
ПРЕПАРАТУ ФС1 В ЛІМФОЦИТАХ
ТА КЛІТИНАХ ПУХЛИНИ ЛЮДИНИ
Досліджували здатність перспективного противі
русного та антибактеріального препарату ФС1 викли
кати пошкодження ДНК та мікроядра в клітинних лі
ніях пухлини людини HeLa і Сасо2 при концентраці
ях 200, 500 та 1000 мкг/мл без екзогенної метаболічної
активації. Препарат був додатково перевірений на
ДНКпошкоджуючу здатність в лімфоцитах людини
при концентраціях 200, 400, 800 мкг/мл. Ні пошкод
ження ДНК, ні формування мікроядер не спостеріга
лось після обробки всіх типів клітин ФС1. Базуючись
на цих результатах, ФС1 може далі вивчатись на
предмет безпеки для потенційного застосування в клі
нічній медицині як антибактеріального/противірус
ного препарату.
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